CFDE Data Portal | Search TMC5-AS1

	Label	Description
	TMC5-AS1 Gene (Entity type)	ENSG00000260592 - TMC5 antisense RNA 1
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE74251 decitabine MCF-7 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 11 V 9 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 trametinib HCC1143 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE234647 1 V 3 REGORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

TMC5-AS1

ENSG00000260592 - TMC5 antisense RNA 1

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE74251 decitabine MCF-7 0 v 3 human dn

A Gene Set from LINCS

GSE239844 11 V 9 CRIZOTINIB HUMAN UP

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE82032 trametinib HCC1143 3 v 1 human dn

A Gene Set from LINCS

GSE234647 1 V 3 REGORAFENIB HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.